246 related articles for article (PubMed ID: 10529677)
1. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
Lusher JM
Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
[No Abstract] [Full Text] [Related]
2. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
[No Abstract] [Full Text] [Related]
3. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
4. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
5. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
Leissinger CA
Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
[No Abstract] [Full Text] [Related]
7. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
8. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
9. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
van der Bom JG; Gouw SC; Rosendaal FR
Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
[No Abstract] [Full Text] [Related]
10. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
[No Abstract] [Full Text] [Related]
11. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
12. Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.
Bray GL
Transfus Med Rev; 1992 Oct; 6(4):252-5. PubMed ID: 1421824
[No Abstract] [Full Text] [Related]
13. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
14. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
15. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
Rothschild C; Laurian Y; Satre EP; Borel Derlon A; Chambost H; Moreau P; Goudemand J; Parquet A; Peynet J; Vicariot M; Beurrier P; Claeyssens S; Durin A; Faradji A; Fressinaud E; Gaillard S; Guérin V; Guérois C; Pernod G; Pouzol P; Schved JF; Gazengel C
Thromb Haemost; 1998 Nov; 80(5):779-83. PubMed ID: 9843171
[TBL] [Abstract][Full Text] [Related]
16. Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
Di Minno MN; Marchesini E; Valdrè L
Blood; 2015 Jun; 125(24):3819-21. PubMed ID: 26069336
[No Abstract] [Full Text] [Related]
17. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
van den Berg HM
Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant factor VIII].
Tusell JM
Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
[No Abstract] [Full Text] [Related]
19. Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.
Ranta S; Koskinen S; Mäkipernaa A
Haemophilia; 2011 Sep; 17(5):e833-4. PubMed ID: 21624011
[No Abstract] [Full Text] [Related]
20. [Hemophilia A with factor VIII inhibitor].
Shima M
Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
